Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.

Nature reviews. Urology - 1 Mar 2018

Hettel Daniel, Sharifi Nima

Abstract excerpt

Patients with advanced prostate cancer who receive androgen deprivation therapy (ADT) almost invariably develop castration-resistant disease. The mechanism of resistance is largely based on synthesis of intratumoral androgens from adrenal precursors, requiring enzymatic action of 3β-hydroxysteroid dehydrogenase/Δ5→4 isomerase 1 (3β-HSD1), encoded by HSD3B1. A nucleotide polymorphism (1245A>C) in HSD3B1 results in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Androstenes
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Multienzyme Complexes

Share to Prostatic Neoplasms

Share to Steroid 17-alpha-Hydroxylase

Share to Steroid Isomerases

Source

Identifiers

PMID: 29231195
DOI: 10.1038/nrurol.2017.201

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.PMID 29231195Read ↗

HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studiesSemantic proximity Read ↗

HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer.Semantic proximity Read ↗

HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.Semantic proximity Read ↗

HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and BeyondSemantic proximity Read ↗

Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.Semantic proximity Read ↗

Association of Missense Polymorphism inHSD3B1With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or AbirateroneSemantic proximity Read ↗

HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.Semantic proximity Read ↗

Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.Semantic proximity Read ↗

HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

<i>HSD3B1</i> genotype among metastatic castration-resistant prostate cancer patients: pharmacodynamics and clinical outcomes after treatment with abiraterone plus prednisoneSemantic proximity Read ↗

Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.Semantic proximity Read ↗

Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.